EIP103 Peptide Degrader Effects on EZH2 in Triple-Negative Breast Cancer

Experimental data from a study on EIP103, a first-in-class peptide degrader targeting the EZH2 protein in triple-negative breast cancer. The dataset includes results from molecular dynamics simulations and biochemical assays demonstrating EIP103's mechanism of action and immunogenic effects. The dataset is small at 4.4 KB, with unknown row and column counts.

Use Cases

• Analyze the binding interaction of the peptide EIP103 with the SET domain of EZH2 using molecular dynamics simulation data.
• Correlate EZH2 expression levels with outcomes to investigate the association with poor prognoses.
• Examine data from biochemical assays on PJA2-mediated ubiquitination and proteasomal degradation triggered by EIP103.
• Assess the impact of EIP103 on immune cell infiltration and lipid peroxidation as markers of immunogenic cell death.

Strengths

• Data originates from a peer-reviewed scientific study published on figshare.
• Includes specific experimental results on a novel therapeutic candidate (EIP103) for a critical disease area.
• The dataset is clearly licensed under CC BY-NC 4.0 for defined reuse.

Limitations

• The dataset is very small at 4.4 KB, indicating limited scope and likely insufficient for standalone statistical modeling.
• The specific data structure, including row count and column names, is unknown, complicating direct analysis.
• Data is focused on a single, novel compound (EIP103), limiting generalizability to other therapeutic approaches.

Provenance

Source

figshare

Collection Method

Experimental research involving molecular dynamics simulations and biochemical assays.

Freshness

Last updated on 2026-03-23.